What does this research mean for the field?

Low-dose aspirin provides significant preventive benefits beyond coronary artery disease, such as reducing preeclampsia risk and colon cancer recurrence, but its use must be balanced against a 1.5 to 2.0-fold increased risk of major bleeding. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review explores the potential uses of low dose aspirin beyond cardiovascular diseases in various medical fields.

July 12, 2026The Egyptian Journal of Internal MedicineOpen Access

Low dose aspirin beyond coronary artery disease: a structured narrative review

Q: What is the clinical evidence from this study?

Study design: Review. Population: Conditions beyond coronary artery disease (e.g., preeclampsia, cancer, rheumatic diseases). Intervention: Low-dose aspirin.

View Full Paper

Ask AI

Bookmark

Key result

Low-dose aspirin benefits high-risk patients but lacks primary prevention value in older adults due to bleeding.

Why the study?

Does low-dose aspirin provide clinical benefits in non-coronary artery disease populations?

Population

Patients with non-coronary artery disease conditions, including high-risk pregnant women, PIK3CA mutated…

Design

Review

Authors

ASAmin Roshdy SolimanCairo University AFAhmed Fayed THTasneem Halaby

Discussion

Member takes

Implication

May support LDA consideration in select non-CVD settings with bleeding caution; leaves open dedicated RCTs for confirmation.

Key Points

This review explores the potential uses of low dose aspirin beyond cardiovascular diseases in various medical fields.
A structured narrative review of literature was performed, searching databases from inception to January 2025 for studies on low dose aspirin beyond coronary artery disease.
Emphasis was placed on epidemiological findings, clinical trials, and health equity perspectives pertaining to low dose aspirin use.
The review synthesized evidence from diverse medical fields and evaluated guideline changes regarding primary prevention.
Low dose aspirin significantly reduces preeclampsia risk in high-risk pregnant women.
In stage II-III colon cancer patients with PIK3CA mutations, low dose aspirin lowered recurrence risk by nearly 50%.
High-risk antiphospholipid syndrome patients showed significant reduction in thrombosis risk; however, major bleeding risk increased 1.5–2.0-fold.

Structured PICO

Does low-dose aspirin provide clinical benefits in non-coronary artery disease populations?

Population

A structured narrative review synthesizing evidence from 312 articles on the use of low-dose aspirin for preventive health beyond coronary artery disease across diverse populations.

Intervention

Low-dose aspirin (LDA)

Low-dose aspirin has potential preventive applications beyond cardiovascular disease, including in preeclampsia, colon cancer, and APS, though bleeding risks require shared decision-making.

Limitations

Profound lack of data on the risk-benefit profile of aspirin in racially and ethnically diverse populations
Major primary prevention trials predominantly enrolled white participants of European ancestry
Heterogeneity of study designs and populations has led to inconsistent recommendations

Cite This Study

Soliman et al. (2026) conducted a review in Conditions beyond coronary artery disease (e.g., preeclampsia, cancer, rheumatic diseases). Low-dose aspirin was evaluated. Low-dose aspirin provides significant benefits in specific high-risk populations, such as reducing preeclampsia risk and lowering recurrence of PIK3CA-mutated stage II-III colon cancer by nearly 50%, but routine primary prevention in older adults is not recommended due to bleeding risks.

synapsesocial.com/papers/6a5331ce4f7abc118adedb57 https://doi.org/10.1186/s43162-026-00677-0

View Full Paper

Ask AI

Bookmark